Development
Cullinan Therapeutics, Inc.
CGEM
$7.85
-$0.235-2.91%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -23.80M | -39.18M | -32.21M | -57.96M | -26.78M |
| Total Depreciation and Amortization | 77.00K | 80.00K | 81.00K | 72.00K | 59.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.29M | 5.14M | 5.78M | 5.71M | 6.75M |
| Change in Net Operating Assets | 3.31M | -181.00K | -4.65M | 1.18M | -5.01M |
| Cash from Operations | -18.13M | -34.14M | -31.01M | -51.00M | -24.98M |
| Capital Expenditure | 0.00 | 0.00 | -49.00K | -159.00K | -882.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 91.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | 0.00 |
| Other Investing Activities | 51.47M | -42.96M | 12.16M | 15.34M | -27.82M |
| Cash from Investing | 51.47M | -42.96M | 12.11M | 15.18M | -28.61M |
| Total Debt Issued | 0.00 | 0.00 | 0.00 | 1.83M | 175.00K |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 248.00K | 112.00K | 38.57M | -- | 194.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 36.00K | -36.00K | -33.28M |
| Cash from Financing | 248.00K | 112.00K | 38.60M | 1.79M | -32.91M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 33.59M | -76.99M | 19.71M | -34.02M | -86.51M |